[go: up one dir, main page]

CA2376284A1 - Methode de prophylaxie et/ou de traitement de troubles cliniques - Google Patents

Methode de prophylaxie et/ou de traitement de troubles cliniques Download PDF

Info

Publication number
CA2376284A1
CA2376284A1 CA002376284A CA2376284A CA2376284A1 CA 2376284 A1 CA2376284 A1 CA 2376284A1 CA 002376284 A CA002376284 A CA 002376284A CA 2376284 A CA2376284 A CA 2376284A CA 2376284 A1 CA2376284 A1 CA 2376284A1
Authority
CA
Canada
Prior art keywords
seq
nucleic acid
acid molecule
igf
chemical analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376284A
Other languages
English (en)
Inventor
Christopher John Wraight
George Arthur Werther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Murdoch Childrens Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376284A1 publication Critical patent/CA2376284A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne généralement une méthode de prophylaxie et/ou de traitement de troubles cutanés, et particulièrement de troubles cutanés inflammatoires et/ou proliférants, et des molécules génétiques utiles dans ces cas. Cette invention a notamment trait à des molécules génétiques capables de moduler l'interaction du facteur de croissance avec son récepteur sur des kératinocytes épidermiques pour inhiber, réduire ou diminuer la stimulation de cette couche des cellules. Dans un mode de réalisation préféré, elle porte sur une méthode de prophylaxie et/ou de traitement du psoriasis.
CA002376284A 1999-06-21 2000-06-21 Methode de prophylaxie et/ou de traitement de troubles cliniques Abandoned CA2376284A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14034599P 1999-06-21 1999-06-21
US60/140,345 1999-06-21
PCT/AU2000/000693 WO2000078341A1 (fr) 1999-06-21 2000-06-21 Methode de prophylaxie et/ou de traitement de troubles cliniques

Publications (1)

Publication Number Publication Date
CA2376284A1 true CA2376284A1 (fr) 2000-12-28

Family

ID=22490818

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376284A Abandoned CA2376284A1 (fr) 1999-06-21 2000-06-21 Methode de prophylaxie et/ou de traitement de troubles cliniques

Country Status (6)

Country Link
EP (1) EP1191941A4 (fr)
JP (1) JP2003502383A (fr)
AU (1) AU768904B2 (fr)
CA (1) CA2376284A1 (fr)
NZ (1) NZ515964A (fr)
WO (1) WO2000078341A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090507A2 (fr) * 2001-05-07 2002-11-14 Thomas Jefferson University Inhibiteurs oligonucleotidiques de la proliferation de cellules cancereuses
US7396922B2 (en) * 2001-11-28 2008-07-08 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense Inhibitory PAS domain protein
KR101166214B1 (ko) 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
JP4338527B2 (ja) 2002-04-05 2009-10-07 サンタリス ファーマ アー／エス ＨＩＦ−１α発現を調節するオリゴマー化合物
BRPI0412279A (pt) * 2003-07-02 2006-09-19 Diversa Corp glucanases, ácidos nucléicos codificando as mesmas e métodos para preparar e aplicar os mesmos
AU2004276226B2 (en) * 2003-08-05 2009-07-30 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
EP1667731B1 (fr) 2003-10-01 2013-05-22 The University Of British Columbia Oligonucleotide bispecifique pour le traitement des malignites du systeme nerveux central
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP1766010B1 (fr) 2004-06-28 2011-02-16 The University Of Western Australia Oligonucléotides antisens permettant d'induire un saut d'exon et leurs procédés d'utilisation
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US7589190B2 (en) 2004-11-09 2009-09-15 Enzon Pharmaceuticals, Inc. Potent LNA oligonucleotides for the inhibition of HIF-1A expression
EP1885855A4 (fr) 2005-05-05 2009-03-04 Valorisation Hsj Soc En Comman Modulateurs du récepteur de la cytokine et leurs utilisations
BRPI0620723A2 (pt) * 2005-12-29 2011-11-22 Alcon Res Ltd inibição de igf1r mediada por rnai para tratamento de angiogênese ocular
ES2427924T3 (es) * 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
WO2008113773A2 (fr) * 2007-03-16 2008-09-25 Biorigen S.R.L. Technique de régulation de l'expression génétique et arn non codant à visée diagnostique et thérapeutique
KR20180118828A (ko) 2008-10-24 2018-10-31 사렙타 쎄러퓨틱스 인코퍼레이티드 Dmd를 위한 다중 엑손 스키핑 조성물
EP3009150B1 (fr) * 2009-02-12 2019-11-13 CuRNA, Inc. Traitement de maladies liées à un facteur neurotrophique dérivé du cerveau (bdnf) par inhibition du transcrit antisens naturel de bdnf
KR101801407B1 (ko) * 2009-07-24 2017-11-24 큐알엔에이, 인크. 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
WO2011022606A2 (fr) * 2009-08-21 2011-02-24 Curna, Inc. Traitement des maladies liées à « l'extrémité c de la protéine chip (protéine interagissant avec hsp70) » par inhibition du transcrit antisens naturel de chip
EP3431603A1 (fr) 2009-11-12 2019-01-23 The University Of Western Australia Molécules antisens et procédés de traitement de pathologies
ES2842938T3 (es) 2012-01-11 2021-07-15 Ionis Pharmaceuticals Inc Composiciones y métodos para la modulación del empalme de IKBKAP
KR20230116945A (ko) 2013-03-14 2023-08-04 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 엑손 스키핑 조성물
BR112015022998A2 (pt) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
NO344051B1 (en) * 2017-05-04 2019-08-26 Patogen As Novel virus in Fish and Method for detection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688793B2 (en) * 1993-09-20 1998-03-19 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
AU692278B2 (en) * 1994-07-08 1998-06-04 Murdoch Childrens Research Institute, The A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
SE9501472D0 (sv) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I

Also Published As

Publication number Publication date
EP1191941A1 (fr) 2002-04-03
JP2003502383A (ja) 2003-01-21
WO2000078341A1 (fr) 2000-12-28
AU5202000A (en) 2001-01-09
AU768904B2 (en) 2004-01-08
EP1191941A4 (fr) 2006-12-13
NZ515964A (en) 2004-03-26
WO2000078341A8 (fr) 2001-03-22

Similar Documents

Publication Publication Date Title
AU768904B2 (en) A method for the prophylaxis and/or treatment of medical disorders
US20030096769A1 (en) Method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
JP6837963B2 (ja) Ｍｉｒ−２９模倣物およびその使用
Yang et al. Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors
Yokoi et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis
Miyake et al. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models
JP6140120B2 (ja) 挫瘡およびその他の状態を治療するためのビスファチン治療薬
JP7323229B2 (ja) ケロイドまたは肥厚性瘢痕の予防または治療用組成物
KR20100027091A (ko) 상처 치유를 위한 개선 방법 및 조성물
Devi et al. Inhibition of human chorionic gonadotropin β‐subunit modulates the mitogenic effect of c‐myc in human prostate cancer cells
EP1513859B1 (fr) Suppresseur kinase de l'inactivation de ras pour traiter la tumorigenese induite par ras
KR20170103841A (ko) Mir-92 억제제 및 이의 용도
Gattone II et al. Renal expression of a transforming growth factor-α transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouse
DE60038680T2 (de) Antisense-therapie für hormonregulierte tumoren
JP2009518022A (ja) 抗ミオシンＶａｓｉＲＮＡおよび皮膚の脱色
US20050261230A1 (en) Method for the prophylaxis and/or treatment of medical disorders
AU692278B2 (en) A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US10907156B2 (en) MiR-127 agents for use in the treatment of renal fibrosis
US20110034381A1 (en) Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH)
JP2021534799A (ja) 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法
JP4484556B2 (ja) 乾癬及び扁平上皮細胞癌の治療のための方法及び医薬組成物
US20070297985A1 (en) Method and composition for enhancing bone formation
Ricker EGF and c-myc in cpk-induced murine autosomal recessive polycystic kidney disease
KR20110093840A (ko) 지방세포 형성의 조절을 위한 ｐｌａｃ８ 활성 억제제의 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead